ValiRx to present at Shares Investor Meeting

RNS Number : 7857I

ValiRx PLC

11 December 2015

 

ValiRx Plc

("ValiRx" or "the Company")

"VALIRX TO PRESENT AT THE SHARES INVESTOR EVENING IN LONDON ON TUESDAY, 15 DECEMBER 2015"

London, UK, 11^th December 2015: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that Satu Vainikka, Chief Executive will be presenting to investors at the free-to-attend Shares Investor Evening in London on Tuesday, 15 December 2015.

The Investor Evening will take place at Novotel Tower Bridge, 10 Pepys Street, London, EC3N 2NR between 18:00 and 20:30 with presentations starting at 18:30.

The Shares Investor Evenings are designed to showcase dynamic companies and provide an opportunity for investors to meet directly with management.

For more information, visit http://www.sharesmagazine.co.uk/events/event/shares-investor-evening-15-dec-15/presenting/ 

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr Satu Vainikka	www.valirx.com
Northland Capital Partners Limited (Broker)	Tel: [phone]
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking)
Peckwater PR	Tel: [phone]
Tarquin Edwards	[e-mail]

Notes for Editors

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.

The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. It actively manages projects within its portfolio as a trading company.  The ValiRx business model spreads the risks of life science technology development by minimizing financial exposure and running a set of projects to defined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.

 2. ValiFinn is the biomarkers and diagnostic development division.  ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology later in the year to strengthen the portfolio.

 3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.

 

END

 

 

NRALIFFAFELLLIE